menu search

zyversa therapeutics announces publication in molecular neurobiology reinforcing data demonstrating that inflammasome asc inhibitor ic 100 attenuates the inflammatory response causing neuronal damage

Molecular Neurobiology publication demonstrated that NLRP3 inflammasomes have an important role in the pathogenesis of multiple sclerosis (“MS”) b...

November 1, 2023, 12:07 pm

zyversa therapeutics announces research published in the peer-reviewed journal diabetes reinforcing ic 100’s rationale for inhibiting asc to attenuate damaging inflammation associated with serious con

Paper reports that obesity exacerbates scarring of the heart’s muscular tissue (myocardial fibrosis) through recruitment of inflammasome ASC to the ...

October 25, 2023, 10:50 am

zyversa therapeutics announces a publication in the peer-reviewed journal, aging, linking inflammasome nlrp3 activation with age-related structural changes in the kidney and reduced kidney function

Chronic kidney disease is most common in people 65 years and older. NLRP3 inflammasomes signaling in the kidneys’ filtration system (“glomerular p...

October 18, 2023, 11:05 am

zyversa therapeutics announces peer-reviewed publication in nature reviews nephrology substantiating var 200’s rationale for mediating transport of cholesterol and lipids out of kidney cells to attenu

This review paper summarizes numerous research studies that address the role of kidney cholesterol and lipid accumulation in the development and progr...

October 11, 2023, 11:05 am

zyversa therapeutics announces peer-reviewed publication in nature reviews nephrology substantiating var 200’s rationale for mediating transport of cholesterol and lipids out of kidney cells to attenu

This review paper summarizes numerous research studies that address the role of kidney cholesterol and lipid accumulation in the development and progr...

October 11, 2023, 11:05 am

zyversa therapeutics’ ceo, stephen c. glover to participate in panel at the bioflorida conference discussing inflammation and its impact on numerous diseases

Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment. ...

September 27, 2023, 11:07 am

zyversa therapeutics announces research published in the journal of clinical investigation reinforcing ic 100’s rationale for inhibiting asc specks to attenuate spread of inflammation into surrounding

Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, ...

September 22, 2023, 10:35 am

zyversa therapeutics announces research published in frontiers in immunology reinforcing ic 100’s rationale for inhibiting multiple inflammasomes to control inflammation in various inflammatory diseas

Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic l...

September 12, 2023, 10:30 am

zyversa therapeutics reports second quarter 2023 corporate and financial results

Key Highlights: Advanced clinical development initiatives for Cholesterol Efflux Mediator™ VAR 200, with planned initiation of a Phase 2a clinical t...

August 21, 2023, 8:15 pm

zyversa therapeutics announces publication in the journal, hepatology, highlighting the role of nlrp3 inflammasome-mediated il-18 in development of liver fibrosis

Liver fibrosis is a progressive form of chronic liver injury mediated by persistent NLRP3 inflammasome activation in liver cells called hepatic stella...

July 15, 2023, 7:16 am

zyversa therapeutics’ ceo, stephen c. glover, is an invited speaker at h.c. wainwright 2nd annual kidney conference to be held virtually on july 25, 2023

zyversa is advancing a dynamic pipeline of drug candidates with multiple programs built around two prop...

July 14, 2023, 11:37 am

zyversa therapeutics announces a publication in journal of the american heart association linking nlrp3 inflammasomes with calcification in arteries of patients with peripheral arterial disease (pad)

PAD, characterized by vascular inflammation and associated calcification, affects 8.5 million people in the United States and contributes to more than...

June 20, 2023, 8:07 pm

European patent office to grant zyversa therapeutics’ patent application for cholesterol transport mediator™ var 200 for use in patients with diabetic nephropathy/diabetic kidney disease

Cholesterol Transport Mediator™ VAR 200 is in development to reduce renal cholesterol and lipid accumulation that damages the kidneys’ filtration ...

June 6, 2023, 1:07 pm

zyversa therapeutics announces changes to zyversa’s board of directors

WESTON, Fla., May 19, 2023 (GLOBE NEWSWIRE) — zyversa Therapeutics, Inc. (Nasdaq: ZVSA, or “...

May 19, 2023, 8:15 pm

zyversa therapeutics announces article published in metabolism pointing to glomerular cholesterol accumulation as key factor exacerbating renal injury and dysfunction in diabetic kidney disease

Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammati...

May 15, 2023, 1:07 pm

zyversa therapeutics reports first quarter 2023 corporate and financial results

Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol ...

May 12, 2023, 1:07 pm

zyversa therapeutics’ ceo, stephen c. glover, to participate in a.g.p.’s virtual healthcare conference

zyversa is advancing a dynamic pipeline of drug candidates with multiple programs built around two prop...

May 11, 2023, 1:07 pm

zyversa therapeutics, inc. announces closing of $11.0 million public offering

WESTON, Fla., May 01, 2023 (GLOBE NEWSWIRE) — zyversa Therapeutics, Inc. (Nasdaq: ZVSA, or “...

May 1, 2023, 10:30 pm

zyversa therapeutics, inc. announces pricing of $11.0 million public offering

WESTON, Fla., April 26, 2023 (GLOBE NEWSWIRE) — zyversa Therapeutics, Inc. (Nasdaq: ZVSA, or “...

April 26, 2023, 1:10 pm

zyversa therapeutics adds dr. douglas golenbock to its inflammatory disease scientific advisory board to support advancement of inflammasome asc inhibitor ic 100

Dr. Golenbock is The Neil and Margery Blacklow Chair in Infectious Diseases and Immunology and Professor and Chief, Division of Infectious Diseases an...

April 24, 2023, 1:07 pm


Search within

Pages Search Results: